OncoMatch/Clinical Trials/NCT06271252

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Is NCT06271252 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies OriCAR-017 for neoplasms, plasma cell.

Phase 1RecruitingOriCell Therapeutics Co., Ltd.NCT06271252Data as of May 2026

Treatment: OriCAR-017 — The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Prior therapy

Min 3 prior lines

Must have received: BCMA-targeted therapy (BCMA bispecific antibody (e.g., teclistamab), BCMA antibody drug conjugate (such as BLENREP), BCMA-CAR-T (such as CARVYKT1TM))

previous exposure to BCMA directed therapies including BCMA bispecific antibody (e.g., teclistamab), BCMA antibody directed conjugate (such as BLENREP), and BCMA-CAR-T (such as CARVYKT1TM)

Cannot have received: autologous hematopoietic stem cell transplantation

Exception: within 8 weeks of Screening Visit or plan to undergo ASCT during the study

Subjects who received autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of Screening Visit or who plan to undergo ASCT during the study.

Cannot have received: allogeneic stem cell therapy

Subjects who received allogeneic stem cell therapy.

Cannot have received: alkylating agent (Bendamustine)

Exception: within 1 year prior to Screening Visit

Received Bendamustine treatment 1 year prior to Screening Visit.

Lab requirements

Blood counts

adequate hematologic function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Cardiac function

adequate cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Northside Hospital · Atlanta, Georgia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify